Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.RSV.preF and RSV preF Protein Phase 1/2a Study in Older Adults
NCT03502707Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2018
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Ad26.RSV.preF, RSV preF Protein in respiratory syncytial virus infection (RSV), sponsored by Janssen Pharmaceutical. Started Jul 2018; status: completed.
02
Drugs
Ad26.RSV.preFRSV preF Protein
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03502707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502707.